Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944838 | 1.00 | CYP1A2 (0.33) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2954815 | 0.94 | TP53 (0.33) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2953155 | 0.94 | TP53 (0.33) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2953158 | 0.94 | TP53 (0.33) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2945352 | 0.85 | CYP1A2 (0.36) | CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2945355 | 0.85 | CYP1A2 (0.36) | CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6504045 | 0.75 | CYP1A2 (0.39) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4442531 | 0.73 | TP53 (0.55) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1238217 | 0.72 | CYP1A2 (0.42) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL21544610 | 0.72 | ALDH1A1 (0.38) | CYP1A2TP53ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20060252839-A1 | Pharmaceutical compositions | BIOGEM S.C.A.R.L. (IT) | 2006-11-09 | — | — | US | disclosed |
| US-20050124665-A1 | Pharmaceutical compositions | ROBERTS STANLEY M (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1487789-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Ltd. (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082813-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124665-A1 | Pharmaceutical compositions | ADCY10, CYP2C19, UGT1A10 | CYP1A2 22/4885TP53 4558/4885ALDH1A1 1040/4885 |
| US-20060252839-A1 | Pharmaceutical compositions | ADK, SYMPK, CYP2J2 | CYP1A2 24/4885TP53 3503/4885ALDH1A1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.